Loading clinical trials...
Loading clinical trials...
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy.
Conditions
Interventions
SHR1020 plus Docetaxel
Placebo plus Docetaxel
Locations
1
China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Start Date
June 1, 2016
Primary Completion Date
November 1, 2016
Completion Date
November 1, 2016
Last Updated
January 18, 2019
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions